

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
21 November 2019 (21.11.2019)



(10) International Publication Number
WO 2019/222154 A1

(51) International Patent Classification:

C07D 401/14 (2006.01) A61K 31/4166 (2006.01)
C07D 401/04 (2006.01) A61P 11/00 (2006.01)
C07D 409/04 (2006.01)

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2019/032127

Published:

— with international search report (Art. 21(3))

(22) International Filing Date:

14 May 2019 (14.05.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/671,753 15 May 2018 (15.05.2018) US

(71) Applicant: **FORESEE PHARMACEUTICALS USA, INC.** [US/US]; 550 S. College Ave., Suite 107, Newark, DE 19713 (US).

(72) Inventors: **YANG, Wenjin**; c/o Foresee Pharmaceuticals USA, Inc., 550 S. College Ave., Suite 107, Newark, DE 19713 (US). **CHANG, Kai-Wei**; c/o Foresee Pharmaceuticals USA, Inc., 550 S. College Ave., Suite 107, Newark, DE 19713 (US). **LIU, Suying**; c/o Foresee Pharmaceuticals USA, Inc., 550 S. College Ave., Suite 107, Newark, DE 19713 (US). **TSAI, Cheng-Han**; c/o Foresee Pharmaceuticals USA, Inc., 550 S. College Ave., Suite 107, Newark, DE 19713 (US).

(74) Agent: **SHANAHAN, Carly, A.** et al.; Panitch Schwarze Belisario & Nadel LLP, Two Commerce Square, 2001 Market Street, Suite 2800, Philadelphia, PA 19103 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

(54) Title: MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF

(57) Abstract: Hydantoin based compounds useful as inhibitors of matrix metalloproteinases (MMPs), particularly macrophage elastase (MMP-12) are described. Also described are related compositions and methods of using the compounds to inhibit MMP-12 and treat diseases mediated by MMP-12, such as asthma, chronic obstructive pulmonary disease (COPD), emphysema, acute lung injury, idiopathic pulmonary fibrosis (IPF), sarcoidosis, systemic sclerosis, liver fibrosis, nonalcoholic steatohepatitis (NASH), arthritis, cancer, heart disease, inflammatory bowel disease (IBD), acute kidney injury (AKI), chronic kidney disease (CKD), Alport syndrome, and nephritis.

